237mn Indians, 1 expired patent, a different kind of opportunity

Semaglutide's Indian patent expired this week. Overnight, 50+ generics flooded the market, crashing the monthly cost from ₹16,000 to ₹1,290. Everyone is celebrating cheaper access to the so-called miracle drug. That celebration is warranted, but incomplete.

Cheap access is incredible, but it isn't distribution. And distribution, in this case, isn't even the deepest problem.

The scale of what's being unlocked

237 million Indians are diabetic or pre-diabetic. That number only grows as urbanisation continues and processed food penetrates deeper into Tier 2 and Tier 3 cities. The GLP-1 wave isn't creating this need - it's surfacing it, and suddenly making a conversation about metabolic health accessible to a population that previously had no affordable entry point. But access to the drug and access to lasting outcomes are two different things.

What the drug does, and what it doesn't

The clinical case for GLP-1 agonists is compelling: significant weight loss, improved insulin sensitivity, and reduced cardiovascular risk. But 60-70% of people who stop the drug regain the weight. The molecule works while you're on it, but when you stop, your body reverts - and most people, eventually, stop.

What the drug does accomplish is something subtler and arguably more consequential. It graduates millions of Indians from "health curious" to "health committed." People who previously couldn't sustain motivation through willpower alone experience, sometimes for the first time, what it feels like to be on the right side of their metabolic health. That experience changes what they're willing to do and what they're willing to pay for.

But the drug leaves them stranded. It’s a drug - so there’s no ongoing support, no follow-up, and no one holding their context. This gap between the pill and the long-term outcome is where we see the more enduring business opportunity is forming - not in the molecule, but in everything that has to happen after it.

We call it the “maintenance layer.” 

It looks like this: it's a sugar alternative sitting on a kitchen counter that turns every morning chai into a micro-commitment. It's a biomarker test where someone sits with you for 45 minutes explaining what your specific results mean for your body - not just handing over a PDF with reference ranges. It's a coach who messages you before Navratri with a plan, not after with a guilt trip.

These products and interactions share a structural feature: they are not episodic and they compound. Each conversation builds on the last, and the value of the relationship grows the longer it persists.

To draw a parallel, the right analogy is your chartered accountant. 

Every Indian professional has a CA they would never switch. They CAs might not be exceptional, but they know the full picture across years, are proactive before tax season rather than reactive after it, and have accumulated context that would take years to rebuild with someone new. 

Now transpose that dynamic onto metabolic health. Someone who holds three years of your biomarker history, flags a pattern in your bloodwork before it becomes a diagnosis, reaches you on WhatsApp (the same place you talk to your family) rather than through a clinical portal you check twice a year. The product isn't a test or a supplement; the product is the relationship with accumulated context. Leaving means starting over from scratch, and that’s exactly why most people won't.

India's trust infrastructure is the distribution moat

This matters because of how health information travels across Indian society. When your mother-in-law recommends a health protocol, she doesn't mention it once - she follows up every week. When a colleague visibly loses weight, you ask what they're doing over lunch. When your grandmother's cholesterol improves, three generations hear about it on Sunday.

India has trust infrastructure that most countries don't. Joint families create built-in accountability networks. We have WhatsApp and community groups that carry health advice through high-trust channels where a forwarded message from a known contact carries more weight than any ad. Soon, recommending your metabolic health person will carry the same social weight as recommending your CA or your doctor. 

The companies building the maintenance layer don't need to manufacture trust from scratch, they need to plug into the networks where it already exists.

We also think AI can accelerate this model rather than replacing it. The advisor who once could hold context for 50 clients can now effectively serve 500 as AI handles the work that would typically slip through the cracks: flagging anomalies in biomarker trends, surfacing the right intervention at the right time, and personalising a nutrition plan before a client even asks. The intermediary's core competency - trust, relationship, human judgment - deepens, and the administrative burden that diluted that competency disappears.

The GLP-1 wave is real. But the companies that build on top of it won't be the ones selling the cheapest pill, as that’s already solved for. They'll be the ones who understood, early, that the pill was only ever the beginning of the relationship.